Disease · MONDO_0013280
myxoid liposarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. myxoid liposarcoma. Diseases, record MONDO_0013280. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0013280
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs24
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRABECTEDIN | CHEMBL450449 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| IFOSFAMIDE | CHEMBL1024 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DACARBAZINE | CHEMBL476 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPIRUBICIN | CHEMBL417 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BROSTALLICIN | CHEMBL1189025 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 24
See all 24 drugsTargets38
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | 3 | Peroxisome proliferator-activated receptor gamma agonist | Phase 2 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 2 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IGF1R | Insulin-like growth factor 1 receptor | 1 | Insulin-like growth factor I receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3480 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 antagonist | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5424 | Drugs and targets |
1 to 10 of 38
See all 38 targetsTrials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00642941 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | Phase 2 | 317 | 2021-02-03 | Sarcoma | TEPROTUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | Phase 2 | 89 | 2020-05-14 | Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Locally Advanced Sarcoma, Liposarcoma | ATEZOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00408434 | Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer | Phase 1 | 32 | 2020-10-19 | Neoplasm | EFATUTAZONE | Its record names the disease | ClinicalTrials.gov |
| NCT00579501 | Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | Phase 2 | 29 | 2014-03-11 | Liposarcoma,Myxoid | DEXAMETHASONE, TRABECTEDIN | Its record names the disease | ClinicalTrials.gov |
| NCT02992743 | Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma | Phase 2 | 23 | 2022-11-28 | Neoplasms | CYCLOPHOSPHAMIDE, FLUDARABINE, LETETRESGENE AUTOLEUCEL | Its record names the disease | ClinicalTrials.gov |
| NCT02249949 | Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | Phase 2 | 15 | 2019-06-27 | Liposarcoma | EFATUTAZONE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01710176 | Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy | Phase 3 | 550 | Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults | DACARBAZINE, DOCETAXEL, EPIRUBICIN, ETOPOSIDE, GEMCITABINE, IFOSFAMIDE, TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02275286 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | Phase 1/2 | 199 | Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma, Pleomorphic Liposarcoma | TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02821507 | Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma | Phase 2 | 70 | Conventional Chondrosarcoma, Myxoid Liposarcoma, Mesenchymal Chondrosarcoma, Dedifferentiated Chondrosarcoma | CYCLOPHOSPHAMIDE, SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | Phase 1 | 50 | Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor | CYCLOPHOSPHAMIDE, SECLIDEMSTAT, TOPOTECAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: deaths from any cause | 31 of 45 | 27 of 44 | 89 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 6 of 45 | 6 of 43 | 88 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Who Experienced At Least One Adverse Event (AE) | 44 of 45 | 43 of 43 | 88 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: serious adverse events | 17 of 45 | 9 of 43 | 88 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) Antibody at Baseline | 14 of 35 | 6 of 29 | 64 | NCT02609984 | Trial comparisons |
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) Antibody After Induction With Treatment | 16 of 32 | 0 of 27 | 59 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) T Cells at Baseline | 17 of 27 | 12 of 24 | 51 | NCT02609984 | Trial comparisons |
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) T Cells After Induction With Treatment | 14 of 26 | 3 of 20 | 46 | NCT02609984 | Trial comparisons |
| Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: deaths from any cause | 5 of 13 | 0 of 10 | 23 | NCT02992743 | Trial comparisons |
| Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: serious adverse events | 5 of 13 | 7 of 10 | 23 | NCT02992743 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 39836945 | DERIVED | 1 | PubMed |
| 38232337 | DERIVED | 1 | PubMed |
| 34260265 | DERIVED | 1 | PubMed |
| 32827353 | DERIVED | 1 | PubMed |
| 32421444 | DERIVED | 1 | PubMed |
| 32077895 | DERIVED | 1 | PubMed |
| 31143880 | DERIVED | 1 | PubMed |
| 28499583 | DERIVED | 1 | PubMed |
| 27733375 | DERIVED | 1 | PubMed |
| 26351345 | DERIVED | 1 | PubMed |
1 to 10 of 14
See all 14 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013280
GET https://conductscience.org/api/diseases/v1/MONDO_0013280/drugs?page=2